common.study.topics.clinical

Dose Optimization Study of Idelalisib in Follicular Lymphoma

common.study.values.description

Dose Optimization Study of Idelalisib in Follicular Lymphoma

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Idelalisib

Idelalisib tablet administered orally

participant.views.study.view.additional

participant.views.study.view.scientific-title

Dose Optimization Study of Idelalisib in Follicular Lymphoma

common.study.values.clinical-trial-id

NCT02536300

participant.views.study.view.id

neg6Dd